Related Experiment Video
Updated: May 31, 2025
09:42
Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
Published on: April 19, 2017
7.4K
Recalcitrant Dermatomyositis Treated With Anifrolumab
Shivang Chaudhary1, Meghan Baumer1, Laura Upton1
1Saint Louis University School of Medicine, St. Louis, Missouri.
ACR Open Rheumatology
|January 24, 2025
Summary
Anifrolumab, a type 1 interferon inhibitor, shows promise for treating severe dermatomyositis (DM) in patients refractory to other treatments. This case study highlights its potential in managing this rare inflammatory myopathy.
Area of Science:
- Immunology
- Dermatology
- Rheumatology
Background:
- Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by distinct skin manifestations.
- Despite available treatments, some DM patients exhibit refractory disease, necessitating novel therapeutic approaches.
- The type 1 interferon (IFN) pathway is implicated in DM pathogenesis and disease activity.
Observation:
- A 38-year-old male patient presented with recalcitrant dermatomyositis, demonstrating resistance to conventional therapies.
- The patient's disease activity showed a correlation with type 1 interferon pathway activity.
Findings:
- Successful treatment of refractory dermatomyositis was achieved using anifrolumab, a monoclonal antibody targeting the interferon α receptor 1 (IFNAR1).
- Anifrolumab effectively managed the patient's severe cutaneous symptoms.
Implications:
- Anifrolumab represents a potential therapeutic option for severe cutaneous dermatomyositis, particularly in treatment-refractory cases.
- Targeting the type 1 interferon pathway with anifrolumab may offer a new strategy for managing refractory DM.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
01:20Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:29Inflammatory Bowel Disease IV: Pharmacological Management
109
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
109
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236